|
![]() |
|
|
Lisinopril
drug data and news
Lisinopril drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Lisinopril | ||
| Brand Names/Synonyms | Acercomp; BL 19; BL-19; HSDB 6852; Inhibril; Linopril; Lisinopril; Lisinopril Dihydrate; Lisipril; Lysinopril; Noperten; Presiten; Prinivil; Prinzide; Renacor; Sinopril; Zestoretic; Zestril | ||
| Indication | For the treatment of hypertension, heart failure and acute myocardial infarction. It may be used alone or in combination with thiazide diuretics | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is used to treat hypertension, congestive heart failure (CHF), postmyocardial infarction, and diabetic nephropathy or retinopathy. Although it is the lysine ester of enalaprilat, the active form of the prodrug enalapril, lisinopril is active unchanged. | ||
| Mechanism Of Action | Lisinopril competes with angiotensin I for its binding site on the angiotensin-converting enzyme (ACE), an enzyme which converts angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative feedback mediator for renin activity, lower angiotensin II plasma levels result in decreased blood pressure and increased plasma renin activity. Baroreceptor reflex mechanisms, stimulated by the fall in blood pressure, release kininase II, an enzyme identical to ACE that degrades bradykinin, a vasodilator. | ||
| Lisinopril News (When available) |
Aurobindo gets USFDA nod for 'Lisinopril' tabs Feb 23, 2006 Aurobindo gets USFDA nod for Lisinopril tabs Feb 23, 2006 Cardiovascular Outcomes in High-Risk Hypertensive Patients ... Feb 8, 2006 Bilateral adrenal masses: phaeochromocytoma or melanoma? Feb 28, 2006 A New Way to Buy Prescriptions Feb 10, 2006 Serial magnetic resonance imaging based assessment of the early ... Feb 8, 2006 Dalal Street Spikes: UTI Bank in limelight Feb 24, 2006 Indian shares flat, Colombo rallies on peace hopes Feb 23, 2006 Packaging to Feb 7, 2006 Necrotizing Fasciitis in a Patient with Type 2 Diabetes Mellitus Feb 9, 2006 Serial magnetic resonance imaging based assessment of the early ... Feb 8, 2006 Packaging to Feb 7, 2006 The colorful ending of the licorice story Jan 17, 2006 Medicure Announces Financial Results for Fiscal Second Quarter ... Jan 10, 2006 'Working poor' join ranks of uninsured Jan 18, 2006 At 3:15 am, Decisions Made In The Dark Jan 22, 2006 Food dyes cause colorful waste Jan 19, 2006 Stock Watch Jan 24, 2006 Loss of taste, smell often tied to high blood pressure, meds Jan 24, 2006 Blue Cross dispensing generics Dec 9, 2005 Lupin receives USFDA approval for Cephalexin capsules Dec 1, 2005 Lupin receives US FDA approval for Cephalexin capsules Dec 1, 2005 Medicare's drug-plan finder can be daunting Nov 14, 2005 Web site errors add to Medicare confusion Dec 3, 2005 Lupin gets nod for antibiotic Cephalexin Dec 1, 2005 Choosing Mom's new drug benefit gave me a headache Nov 17, 2005 US drug industry's credibility gap Nov 14, 2005 For The Drug Industry, A Number Of Bitter Pills Nov 14, 2005 Gender-related differences in left ventricular structural and ... Nov 23, 2005 Aging just one cause for loss of taste Nov 21, 2005 Lupin gets USFDA nod for Lisinopril tablets Sep 13, 2005 Lupin gets USFDA approval for Lisinopril ANDA Sep 13, 2005 Lupin gets US nod for lisinopril tablets Sep 13, 2005 Lupin receives FDA approval for lisinopril tablets Sep 23, 2005 Medicure Meets Primary Endpoints in Phase II Diabetic Hypertension ... Sep 14, 2005 Lupin gets USFDA approval for ANDA Sep 13, 2005 Changing of hair color unusual reaction to drug Sep 29, 2005 Medicure shares rise after cardioprotective drug gets on FDA fast ... Sep 21, 2005 Medicure achieves 'primary endpoints' in diabetic hypertension ... Sep 14, 2005 Best Treatments: Managing Heart Failure Sep 24, 2005 Medicure surges on positive test results Sep 15, 2005 Wrap up: Sensex ends at a new high Sep 13, 2005 People on the Move Sep 21, 2005 FDA Safety Labeling Changes: Requip, Lodine, Zestril Aug 24, 2005 FDA Safety Labeling Changes: Clozaril, Pegasys, Zestoretic Aug 17, 2005 Top 20 drugs sought on Internet Aug 12, 2005 Cholesterol drug has surprising, hairy side effect Aug 31, 2005 Drugs lower cholesterol -- and may turn gray hair dark Aug 22, 2005 Senior Corner: Be ready to choose among drug plans Aug 16, 2005 | ||
| Dosage Forms | Tablets | ||
| Drug_Category | Cardiotonic Agents; Antihypertensive Agents; Angiotensin-converting Enzyme Inhibitors; ATC:C09AA03 | ||
| Absorption | Approximately 25%, but widely variable between individuals (6 to 60%) | ||
| Interactions |
-->Interactions for Lisinopril: Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with PRINIVIL. The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with PRINIVIL. If it is necessary to continue the diuretic, initiate therapy with PRINIVIL at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized. When a diuretic is added to the therapy of a patient receiving PRINIVIL, an additional antihypertensive effect is usually observed. Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic. Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of lisinopril may result in a further deterioration of renal function. These effects are usually reversible. Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors, including lisinopril. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant. Other Agents: PRINIVIL has been used concomitantly with nitrates and/or digoxin without evidence of clinically significant adverse interactions. This included post myocardial infarction patients who were receiving intravenous or transdermal nitroglycerin. No clinically important pharmacokinetic interactions occurred when PRINIVIL was used concomitantly with propranolol or hydrochlorothiazide. The presence of food in the stomach does not alter the bioavailability of PRINIVIL. Agents Increasing Serum Potassium: PRINIVIL attenuates potassium loss caused by thiazide-type diuretics. Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. Potassium sparing agents should generally not be used in patients with heart failure who are receiving PRINIVIL. Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. Lithium toxicity was usually reversible upon discontinuation of lithium and the ACE inhibitor. It is recommended that serum lithium levels be monitored frequently if PRINIVIL is administered concomitantly with lithium. | ||
| Toxicity | hypotension, LD50= 2000 mg/kg(orally in rat) | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 1-[6-amino-2-(1-carboxy-3-phenyl-propyl)amino-hexanoyl]pyrrolidine-2-carboxylic acid dihydrate | ||
| Chemical Formula | C21H31N3O5 | ||
| Molecular Weight | 405.488 g/mol | ||
| Smiles String | C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O | ||
| Melting Point | Not Available | ||
| Water Solubility | 13 mg/L | ||
| State | white to off-white, crystalline powder | ||
| LogP/Hphobicity | -1.22 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | excreted unchanged entirely in the urine | ||
| Half Life | 12 hours | ||
| Protein Binding [%] | Lisinopril does not appear to be bound to other serum proteins | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Lisinopril.html http://www.rxlist.com/cgi/generic/lisinop.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00560 | ||
| CAS Registry Number | 83915-83-7 | ||
| KEGG Compound ID | C07077 | ||
| PubChem ID | SID:205105 | ||
| PharmGKB ID | PA450242 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2217538 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |